Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

53.44 -0.09 (-0.16%)
Streaming Delayed Price Updated: 11:54 AM EDT, Jun 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2023
Via Benzinga
Exact Sciences (EXAS) Q2 2023 Earnings Call Transcript
EXAS earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Exact Sciences, A Cathie Wood Darling, Just Reported A Sixth Big Sales Quarter
The company is a leader in using diagnostics to screen for early cancer cases. 
Via Investor's Business Daily
Earnings Preview For Exact Sciences
Via Benzinga
Accenture, Hewlett Packard Enterprise And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
2 Revolutionary Stocks to Buy and Hold for 10 Years
Breaking new ground can be highly lucrative. 
Via The Motley Fool
Expert Ratings for Exact Sciences
Via Benzinga
Cathie Wood's Ark Invest Continues To Sell Shares Of Warren Buffett-Backed BYD — Coinbase Holdings Trimmed As Well
Via Benzinga
Cathie Wood's Ark Invest Makes Major Moves In This Warren Buffett-Backed EV Company, Moderna
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Growth Stocks Every Investor Should Know About Now
While a countless number of ideas flood the capital markets, these must-know growth stocks should be on your radar. 
Via InvestorPlace
2 Cathie Wood Growth Stocks That Could Make You Richer
These two biotechs could be winning plays for aggressive investors. 
Via The Motley Fool
Analyst Ratings for Exact Sciences
Via Benzinga
Canaccord Genuity Maintains Buy Rating for Exact Sciences: Here's What You Need To Know
Via Benzinga
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating
On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. 
Via Investor's Business Daily
ETF Returns: Mid-Cap Winners And Losers
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on... 
Via Benzinga
Analysts Think This Soaring Cathie Wood Stock Has Peaked. Are They Right?
Is it a matter of time before Exact Sciences stock starts giving back some of its impressive gains this year? 
Via The Motley Fool
Cathie Wood's Ark Outshines S&P 500, Nasdaq In H1: Here Are The Major Trades It Made
Via Benzinga
This Big Cathie Wood Stock Is Outperforming Even Tesla
DraftKings is the strongest performer among Ark Invest's major holdings. 
Via Investor's Business Daily
Cologuard's Improved Performance to Accelerate Growth, Analyst Raises Expectations
Tuesday, Exact Sciences Corp (NASDAQ: EXAS) announced topline results from the pivotal BLUE-C study, showing that next-generation  
Via Benzinga
Stock Market Pulls Back After Several Weeks Of Gains: Weekly Review
But the major indexes and leading stocks generally showed healthy action. 
Via Investor's Business Daily
Exact Sciences Set To Dominate Emerging Precision Oncology Market: Analyst Applauds $18B Potential Market
Benchmark analyst Bruce D. 
Via Benzinga
2 Stocks to Invest $500 In and Hold For 10 Years
Both companies have outperformed the market over the past year. 
Via The Motley Fool
Exact Sciences Stock Is Trading Higher: What's Going On?
Exact Sciences Corp (NASDAQ: EXAS) shares are trading higher Wednesday after the cancer screening and diagnostics company said its Cologuard test demonstrated 94% sensitivity for  
Via Benzinga
Why Exact Sciences Stock Is Moving Higher After Hours
Exact Sciences Corp (NASDAQ: EXAS) shares are rising in extended trading Tuesday after the cancer screening and diagnostics company said its Cologuard test demonstrated 94% sensitivity for  
Via Benzinga
Why Exact Sciences Stock With 219% Growth Could Surge Again
The company is trying to top its own success in colon cancer screening. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Revolutionary Companies With Trillion-Dollar Potential
These are just a few of the trillion-dollar potential companies to put on your radar screen for the second half. 
Via InvestorPlace
This Analyst With 87% Accuracy Rate Sees Around 16% Upside In Home Depot - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts
The S&P 500 settled higher on Friday, surpassing the 4,300 level for the first time since August. The index also recorded gains for four weeks in a row. 
Via Benzinga
Why Top 2% Stock Exact Sciences Is On An Eight-Month Hot Streak — And Nearing A Profit-Taking Zone
The colon cancer screening market is vast, and underserved. Exact Sciences wants to change that. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.